We have detected that you are using some form of ad-blocking or filtering.
Please consider white-listing Labnodes since 1) ad-blockers like uBlock break Labnodes functionality and 2) Labnodes does not serve ads.
Many end-stage renal disease patients receive thrice-weekly hemodialysis (HD) and report impairments in health-related quality of life (HRQOL). Recent studies indicate that short daily HD may improve HRQOL. High-quality studies exploring the burdens and costs to patients, caregivers, and society are necessary before widespread adoption can be advocated. Further research exploring the mechanisms by which these benefits are realized is also important, as many patients are likely to opt out of short daily HD.
© 2010-2021. All Rights Reserved to Vanderbilt University. Vanderbilt University is committed to principles of equal opportunity and affirmative action.
Released July 13, 2020